v-A total of 93 patients with intractable spasticity due to either spinal cord injury (59 cases), multiple sclerosis (31 cases), or other spinal pathology (three cases) were entered into a randomized double-blind placebocontrolled screening protocol of intrathecal baclofen test injections. Of the 88 patients who responded to an intrathecal bolus of 50, 75, or 100 ug of baclofen, 75 underwent implantation of a programmable pump system for chronic therapy. Patients were followed for 5 to 41 months after surgery (mean 19 months). No deaths or new permanent neurological deficits occurred as a result of surgery or chronic intrathecal baclofen administration. Rigidity was reduced from a mean preoperative Ashworlh scale score of 3.9 to a mean postoperative score of 1.7. Muscle spasms were reduced from a mean preoperative score of 3.1 (on a fourpoint scale) to a mean postoperative score of 1.0. Although the dose of intrathecal baclofen required to control spasticity increased with time, drug tolerance was not a limiting factor in this study. Only one patient withdrew from the study because of a late surgical complication (pump pocket infection). Another patient received an intrathecal badofen overdose because of a human error in programming the pump. The results of this study indicate that intrathecal baclofen infusion can be safe and effective for the long-term treatment of intractable spasticity in patients with spinal cord injury or multiple sclerosis.
C
HRONIC, medically intractable spasticity and rigidity contribute significantly to the disability of patients with spinal cord injuries or multiple sclerosis. Muscle spasms and increased motor tone can make transfers, sitting, and hygiene difficult or impossible for patients with severe or complete spinal cord lesions, and can impair ambulation and self-care in patients with incomplete lesions. While oral antispasmodic medications and physical therapy are effective in many patients, others do not respond satisfactorily. Orally administered baclofen, diazepam, dantrolene sodium, and other drugs sometimes cause intolerable central nervous system (CNS) side effects or systemic toxicity at the dose levels required to achieve a therapeutic response, m.~6,2o-= Recently, the chronic intrathecal administration of baclofen using an implanted pump and catheter system has demonstrated promising results in the control of spasticity and rigidity of spinal originy.7-, u6-2~ This mode of therapy represents a potentially significant advance over destructive procedures in patients with preserved function or in those unwilling to accept the finality of another surgically induced spinal cord lesion. To further assess the longterm safety and efficacy of intrathecal baclofen, we carried out the nationwide (United States) multicenter study described in this article.
Clinical Material and Methods

Patient Population
Between May, 1988, and July, 1990, 93 adult patients with chronic, medically intractable spasticity of spinal origin due to either spinal cord injury (59 cases), multiple sclerosis (31 cases), or other spinal pathology (three cases) were selected to undergo a screening protocol of intrathecal baclofen (Lioresal) test injections. The resuits determined whether they would be candidates for long-term therapy using an implantable, externally programmable pump and catheter system.* The clinical features of the 93 patients who underwent trial screening and the 75 who had pump implantations are summarized in Table 1 . Fifteen centers in the United States participated in this investigation under a uniform protocol approved by the Food and Drug Administration and by each center's institutional review board (see Appendix). All patients gave informed consent before being entered into the study. The operation and features of the pump system have been described previously. 2'~176 Patient selection and exclusion criteria are listed in Table 2 . Patients over 65 years of age entered the study as "compassionate use" exceptions. The quantitative assessment scales for rigidity (Ashworth scale) j7.~s'2~ scores and muscle spasms are summarized in Table 3. *Synchromed infusion system manufactured by Medtronic, Inc., Minneapolis, Minnesota. 100 ug baclofen or placebo * Test injections were randomized by coin toss on Day 1 (and Days 3 and 5, if necessary). Ifa patient responded to active drug at any dose level, the higher trial doses were not administered.
Test Injections
The patients and the evaluating physicians were blinded as to whether a particular test injection was baclofen (active drug) or placebo (saline). The incremental protocol for test injections of baclofen (50, 75, or 100 ug) depended upon the patient's response at each dose level (Table 4) . Test doses were administered by lumbar puncture or by placement of a temporary intrathecal catheter. After each bolus injection of drug or placebo, the following parameters were recorded at 0.5, 1, 2, 4, 8, and 24 hours: respiratory rate, pulse rate, blood pressure, hypertonia (Ashworth scale), reflexes, spasm score, voluntary muscle movement, and adverse effects (if any).
Patients were offered pump implantation if they showed a positive response, which was defined as a twopoint reduction in the Ashworth scale and muscle spasm scores for at least 4 hours after a bolus infusion of active drug. Patients were excluded from pump implantation if they did not respond to the maximum (100/ag) test dose or if they experienced intolerable side effects from the test dose. Prescreening patient assessment included a complete medical history and physical and neurological examinations. Current and prior antispasmodic medications and other treatments, including surgical procedures, were recorded. The Ashworth scale in the lower extremities was recorded at baseline, during screening, at hospital discharge, at 2 weeks postdischarge, and at 30-day intervals for 12 months. At the same intervals, lower-extremity reflexes were recorded on a six-point scale, spontaneous spasms were Left: Ashworth scale scores over time since pump implantation. Center: Spasm frequency scores over time since pump implantation. Right." Intrathecal baclofen doses over time since pump implantation. "Baseline"
and "4-hr post" refer to scores before and 4 hours after the test injection to which the patients responded. The number of patients observed at longer time intervals decreased because the pumps were implanted over a 26-month period.
recorded on a five-point scale, and voluntary muscle movement was recorded as "improved," "unchanged," or "worse" in relation to the previous examination. A serum chemistry profile was performed before screening and at 6 and 12 months after pump implantation. All data were collected by the investigators at each center and submitted to the central study office for analysis.
Eighty-eight patients (94.6%) responded to the test dose injections, although two (2.2%) of these experienced side effects that precluded further participation in the study. No patient responded to the placebo in this study. Eleven patients who met the drug-response criteria declined further participation for a variety of medical, personal, or administrative reasons. The remaining 75 patients underwent pump implantation for long-term administration of intrathecal baclofen. These patients form the basis for this report.
Surgical Procedure and Postoperative Care
The pump was implanted into a subcutaneous pocket in the anterior abdominal wall with the patient under local or general anesthesia, and connected via tubing tunneled subcutaneously to a lumbar subarachnoid catheter inserted into the spinal canal using a Tuohy needle. Intraoperatively, the pump was filled with baclofen solution and programmed to administer a total daily dose approximately equal to double the screening dose to which the patient had responded. Postoperatively, oral antispasmodic medications were tapered gradually so as to avoid withdrawal seizures. Before hospital discharge, the intrathecal baclofen dose was titrated to achieve an optimum clinical effect. Patients were examined 2 weeks after pump implantation and at least every 30 clays thereafter for the 1st year. During these evaluations, the pumps were refilled and the baclofen concentration, dose rate, or infusion mode adjusted as needed to maintain the desired clinical effect. After the 1 st year, pump refills were scheduled on an individual basis at intervals of up to 3 months. The infusion rate and mode (continuous, complex stepfunction, or intermittent timed bolus) were adjusted by telemetry using a briefcase-sized programmable computer. Intensive physical and rehabilitation therapy were instituted for most patients postoperatively to maximize the functional gains of reduced spasticity.
Results
Follow-Up Study
Patients were followed for a mean of 19 months (range 5 to 41 months) after pump implantation or until death (three cases) or study withdrawal (two cases). No patient died or developed a new or increased neurological deficit as a result of chronic intrathecal baclofen administration. To date, no patient has required a destructive surgical or neurolytic procedure.
At last follow-up examination, the mean Ashworth scale score for the entire group had decreased from a preoperative value of 3.9 to a postoperative value of 1.7 ( Fig. 1 left) . The results did not differ significantly between patients with spinal cord injury (mean Ashworth scale score 3.9 before surgery vs. 1.8 after surgery) and those with multiple sclerosis (mean Ashworth scale score 2.9 before surgery vs 1.6 after surgery). The mean muscle spasm score for the study group also decreased, from a preoperative value of 3.1 to a postoperative value of 1.0 (Fig. 1 center) . The degree of reduction in muscle spasms did not differ significantly between spinal cord-injured patients (mean spasm score 3.3 before surgery vs. 1.3 after surgery) and multiple sclerosis patients (mean spasm score 2.7 before surgery vs. 0.7 after surgery). This observed reduction in rigidity and muscle spasms tended to remain stable over time. The daily dose of intrathecal baclofen required to maintain a therapeutic effect rose from a mean starting close of 187 ug/day to 405 ug/day by the end of the study period (Fig. 1 right) . Both the initial daily dose and the daily dose at last follow-up evaluation tended to be higher for patients with spinal cord injury (mean starting dose 196 ug/day, mean dose at follow-up study 462 ug/day) than for patients with multiple sclerosis (mean starting dose 171 ug/day, mean dose at follow-up study 320 ug/day). This difference was statistically significant (p < 0.05, Wilcoxon two-sample rank-sum test).
Aside from marked reduction in motor tone, no other long-term neurological effects were observed in these 
Drug Tolerance
Six (8%) of the 75 patients developed an episode of suspected tolerance to the effects of intrathecal baclofen bewteen 3 and 31 months after pump implantation; one of these patients had two episodes. Three patients had multiple sclerosis (11% of multiple sclerosis patients) and three had spinal cord injury (6.4% of the spinal cord injury patients). The daily intrathecal baclofen dose at which tolerance was diagnosed by individual investigators varied from 120 to 960 ug/day (mean 385 ug/day). Suspected drug tolerance was treated with a 3-to 37-day baclofen "drug holiday." During these episodes, the patients' pumps were filled with preservativefree saline (three cases), morphine (0.5 to 2 rag/day; four cases), or Dilaudid (hydromorphone hydrochlofide, 0.3 mg/day; one case). In one patient, during a single intraspinal baclofen withdrawal period, the pump was fflled first with morphine solution, then refilled with saline. Intrathecal baclofen was resumed after the drug holiday at a lower daily dose than before on five occasions and a higher daily dose on two occasions. One patient, a 40-year-old woman with a 14-year history of spasticity due to multiple sclerosis, eventually withdrew from the study 1 year after an episode of drug tolerance was treated successfully. The other five patients resumed intrathecaI baclofen therapy for the duration of the study (range 3 to 24 months).
Complications and Side Effects
Three patients with implanted pumps died of causes probably unrelated to intrathecal baclofen administration. A 57-year-old man with a T-6 spinal cord injury (caused by an epidural abscess years earlier) died at home of cardiorespiratory failure 11 months after pump implantation. In the second patient, a 54-year-old woman with myelopathy from systemic lupus erythe- matosus, death was caused by progression of the multisystemic disease. The third patient who died was a 43-year-old man with a C-6 spinal cord injury. An autopsy by the county coroner suggested that hypertensive cardiomyopathy caused his unwitnessed death at home. The level of baclofen in the cerebrospinal fluid (CSF) was not determined, and the patient was buried with the pump still in place. All three patients had their spasticity controlled satisfactorily by intrathecal baclofen for the duration of their survival after pump placement.
Pump-related surgical complications are listed in Table 5. One superficial wound infection resolved with antibiotic administration and local wound care. One patient suffered a deep pump-pocket staphylococcal infection 5 months after surgery, resulting in system explantation and withdrawal from the study. Pump pocket erosion necessitated surgical repair in one patient and pump replacement in another. Mechanical failures required removal and replacement of the device.
Twenty-two catheter malfunctions occurred in 18 patients; all were repaired easily without long-term sequelae. Other miscellaneous device-related complications included one instance of subcutaneous drug extravasation during pump refill, one pump pocket seroma that resolved with aspiration, one CSF leak that required fascial repair, and one instance of pump-site discomfort that resolved after repositioning the device.
Drug-related complications or side effects occurred in 11 patients (Table 6 ), either during the screening period (three cases) or during chronic intrathecal administration (eight cases). All were reversed by appropriate treatment.
Two patients suffered seizures. One, a 55-year-old woman with multiple sclerosis, experienced a single complex partial and focal motor seizure associated with clinical and imaging-documented progression of her disease 12 months after surgery. Phenytoin was administered, and no further seizures occurred. The second patient was a 28-year-old man with a cervical spinal cord injury who had a generalized seizure 4 days after discontinuing oral diazepam (5 rag/day). Surgical exploration of the pump and catheter disclosed that fi-brous tissue had occluded the tubing. This condition was repaired, no further seizures occurred, and chronic administration of anticonvulsants was not required.
Respiratory depression occurred in two patients, one of whom required temporary ventilatory support. This patient was a 55-year-old woman with multiple sclerosis whose daily dose of baclofen was to be increased. An operator error in programming the pump caused her to receive 138 ug/hr instead of 138 ~g/day. After a few hours, she became comatose; the patient was hospitalized and required temporary mechanical ventilation. Physostigmine administration did not reverse the respiratory depression or unconsciousness. ~4' 23 Once the programming error was discovered, the patient recovered and chronic intrathecal baclofen administration resumed.
Hypotension without respiratory" depression accompanied systemic infections (urosepsis or pneumonia with septicemia) in two patients and resolved after antibiotic therapy. In another patient, a 25-year-old woman with cervical spinal cord injury, a test injection of 50 t~g intrathecal baclofen caused hypotension which was treated by placing the patient's bed in the headdown position. In this case, pump implantation was not performed. Hypertension occurred in a patient with a cervical spinal cord injury whose pump ran dry; he had been receiving intrathecal baclofen at a dose of 900 ug/day. His blood pressure normalized after the administration of nifedipine, and intrathecal baclofen infusion was resumed.
Miscellaneous, possibly drug-related events included mental depression in two patients, repeated episodes of drowsiness, dizziness, and nausea in one, and upperextremity weakness in one. The latter patient was a 69-year-old woman with multiple sclerosis who experienced temporary right-arm weakness after a test injection of 50ug intrathecal baclofen; because of this side effect, pump implantation was not performed.
Discussion
Pharmacology
Baclofen (4-amino-3(p-chlorophenyl)butyric acid) is structurally similar to -r-aminobutyric acid (GABA) and binds to presynaptic GABA-B receptors within the brain stem, dorsal horn of the spinal cord, and other CNS sites. 6~24-27 Baclofen reduces muscle tone and vasospasms by suppressing the release of excitatory neurotransmitters involved in monosynaptic and polysynaptic reflexes. ~2.~3 While orally administered baclofen is a highly effective antispasmodic drug, it reaches only relatively low concentrations in the spinal cord and CSF, even after large systemic doses. Thus, many patients experience cerebral side effects such as drowsiness and confusion at the dosages required to reduce spasticity at the spinal cord level Laboratory studies of baclofen administered directly into the lumbar CSF of animals established the dosage parameters necessary to begin human trials. 6'9'25 '26 Delivering baclofen directly into the lumbar subarachnoid space permitted high levels of drug to diffuse into the superficial layers of the spinal cord dorsal horn while avoiding the cerebral side effects of oral baclofen administration. The results have been dramatic in patients with spasticity of spinal cord or supraspinal origin. ~5"8 '9 While the screening phase of the current study was double-blinded and placebo-controlled, another randomized double-blind crossover study investigated the effects of 72 hours of continuous intrathecal baclofen infusion versus placebo .2, In that study, as in the present one, no patient responded to placebo; all patients who responded to a screening dose of intrathecal baclofen continued to have relief of spasticity during long-term therapy.
Clinical Monitoring
To date, over 800 patients worldwide have been treated with intrathecal baclofen. The present report describes the largest uniformly treated and studied patient group in the United States. Our results confirm the suggestions of earlier reports that intrathecal baclofen can be a safe and effective long-term treatment for intractable spasticity. Patients who underwent pump implantation in the present study are still under observation as part of a Phase III study involving additional centers and patients. In the future, even longer-term follow-up evaluation will be available for this cohort.
A number of factors are important to achieve satisfactory results. First, during the screening phase, patients must be monitored closely in a hospital setting to detect alterations in vital signs and/or neurological status? Second, an implantable programmable pump is necessary to provide flexibility in drug delivery for patients whose drug requirements may vary in a circadian fashion or over longer time periods. Third, while no special patient care is required between outpatient visits for pump refills, it is important to schedule refill sessions before the reservoir runs completely dry. A faintly audible alarm can be set to warn the patient that the drug reservoir level is low (usually ~ 2 ml). If the pump runs dry, patients will experience a rapid return of their preoperative spasticity. However, one patient in this study who was receiving a very high daily intrathecal baclofen dose (900 t~g/day) suffered hypertension and autonomic instability until the pump was refilled and baclofen infusion resumed. Another patient experienced a seizure that may have been due to acute withdrawal of intrathecal baclofen and oral Valium (diazepam). Fourth, close attention to surgical detail is necessary in handling, positioning, and securing the fragile catheter tubing. Twenty-two catheter-related system malfunctions occurred in 18 patients in this study, all of which were repaired easily. Further experience and refinements in catheter design should reduce the number of such events in the future. Finally, patients with open, infected decubitus ulcers may be at increased risk for the development of a deep pump pocket infection. As in patients with infected shunt systems, replacement of a new pump after elimination of the original infection may be a safe procedure. Fortunately, such cases are rare, and decisions must be individualized.
No intraspinal infections occurred in this patient series. The use of aseptic technique during pump refills, the incorporation of a bacteria-retentive filter in the pump itself, and the addition of an in-line filter to each refill kit have all contributed to a low infection rate.
Drug-Related Side Effects
Among the 11 patients who experienced drug-related side effects during screening or long-term therapy, eight had cervical spinal canal injuries (five men and three women). Since 39 patients with cervical spinal cord injuries were screened (36 men and three women), 20.5% of this group, including all three women, experienced at least a minor adverse event that could have been drug-related. This suggests that patients with cervical spinal cord injuries, especially women, may be more vulnerable to drug-induced side effects. There does not appear to be any gender-related risk of adverse events in multiple sclerosis patients.
Drug Tolerance
As expected, the mean daily dose of intrathecal baclofen required to maintain a therapeutic effect increased with time. Because the definition of tolerance was not established at the outset of this study, judgments as to whether individual patients were becoming tolerant to intrathecal baclofen were left to the investigators at each center. In retrospect, only two patients were receiving intrathecal baclofen at doses higher than the mean plus one standard deviation at the time tolerance was diagnosed (596 ug/day at 3 months, 960 #g/ day at 10 months). Both patients resumed intrathecal baclofen at a dose of 192 ug/day after substitution of intrathecal morphine for 14 or 28 days. We now believe that the diagnosis of drug tolerance should be reserved for patients whose intrathecal baclofen requirement significantly exceeds the mean for the number of months they have been under treatment. Under such circumstances, intrathecal baclofen should be withdrawn gradually. Substitution of oral medication and/ or intraspinal morphine for 2 to 4 weeks should restore the patient's sensitivity to intrathecal baclofen, allowing treatment to resume at a dose rate close to the patient's initial postoperative drug requirement.
Conclusions
Severe spasticity of spinal origin responds dramatically to the long-term intrathecal administration of baclofen. The programmable pump permits sufficient flexibility in drug dose rate and patterns to accommodate the lifestyle needs of patients with some preserved motor or sensory function. The surgical procedure of pump and catheter implantation is safe and carries virtually no risk of causing a permanent new or increased neurological deficit. The incidence of serious complications related to the drug or to the drug administration device has been low. We believe a screening trial of intrathecal baclofen should be considered for any patient with severe intractable spasticity of spinal origin. In patients who respond to a test dose of up to 100 ug, chronic intrathecal baclofen may now be the treatment of choice. In the future, this mode of therapy may prove useful for the treatment of spasticity due to cerebral palsy, motoneuron disease, stiff-man syndrome, and other neurological conditions.l'415
